Latest news
SKYSCRAPER-03 Trial: Critical Setback for TIGIT Consolidation in Stage III NSCLC - OncodailyOncodaily · Sat, 08 Aug 2026 11:36:12 GMTFDA Approves Tudriqev for Anti-PD-1 Resistant Advanced Melanoma - The Clinical Trial VanguardThe Clinical Trial Vanguard · Fri, 07 Aug 2026 07:31:37 GMTCan Diet and the Gut Microbiome Improve Immunotherapy Response? - OncodailyOncodaily · Wed, 05 Aug 2026 16:20:28 GMTDual Checkpoint Blockade Boosts Breast Cancer pCR - MedscapeMedscape · Wed, 05 Aug 2026 12:19:22 GMTIn Squamous NSCLC, Cemiplimab Data Pulled the Room Away From Dual Checkpoint Blockade - Targeted OncologyTargeted Oncology · Tue, 04 Aug 2026 17:39:36 GMTCombining KRAS Inhibitors With PI3K and Checkpoint Blockade to Improve Response Durability - CancerNetworkCancerNetwork · Sat, 01 Aug 2026 16:03:25 GMTHow Checkpoint Inhibition Is Used in Locally Advanced Disease - OncLiveOncLive · Fri, 31 Jul 2026 12:14:24 GMTPembrolizumab-Induced Checkpoint Inhibitor-Associated Diabetes Mellitus in Triple-Negative Breast Cancer: A Case Report - CureusCureus · Sun, 26 Jul 2026 07:00:00 GMT